ArticleLeukemia2013

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

R C Prins et al.PubMed ↗Publisher ↗

No numbers read from the abstract.